Pharmacoeconomics: Identifying the Issues

ISPOR, U.S. Health and Human Services (HHS), Agency for Health Care Policy and Research (AHRQ), and the Health Outcomes Work Group of the Pharmaceutical Research and Manufacturers of America (PhRMA), co-sponsored and convened an Advisory Panel Meeting and Conference on Pharmacoeconomic Issues in February 1998.

The objective of this interdisciplinary conference was to identify the issues in conducting pharmacoeconomic studies, interpreting the results of these studies, and using pharmacoeconomic information in health care decisions. The results of this meeting and conference are summarized in the following reports that were published in Value in Health 1999, Volume 2, Number 2, pages 67-112.

Executive Summary
Pharmacoeconomics: Identifying the Issues Overview and Advisory Panel Report Summary
Panel I: Methodological Issues in Pharmacoeconomic Evaluations—Clinical Studies
Panel II: Methodological Issues in Conducting Pharmacoeconomic Evaluations—Modeling Studies
Panel III: Methodological Issues in Conducting Pharmacoeconomic Evaluations—Retrospective and Claims Database Studies
Panel IV: Education and Skills Needed to Conduct, Interpret, and Use Economic Evaluations in Healthcare
Panel V: Application of Healthcare Intervention Economic Evaluations in Healthcare Decision-Making
Panel VI: Addressing Questions of Bias, Credibility, and Quality in Health Economic Evaluations
Panel VII: Communication and Reporting Health Economic Information